National, 16 April 2025: ZEISS Medical Technology
continued to push the boundaries of surgical precision and workflow efficiency
with the introduction of its latest innovations at the APAO AIOC 2025. These
include the ZEISS ARTEVO 850 and ARTEVO 750 ophthalmic microscopes, the AT
ELANA® 841P trifocal Intraocular Lens (IOL), and the ZEISS CIRRUS PathFinder AI
decision support tool – all designed to empower surgeons with enhanced
visualization, premium lens technology, and artificial intelligence-driven
insights.
ZEISS Medical Technology’s exhibit area, positioned
at a strategic location at the event, drew a significant audience of over
7000-8000 delegates, solidifying its position as a pivotal brand for advancing
ophthalmology sector in India.
Advancing Surgical Visualization with the ZEISS
ARTEVO Portfolio
ZEISS India expanded its high-end microscope
portfolio with the ZEISS ARTEVO 850 3D heads-up ophthalmic microscope, will
lead the way in digital visualization. With true color imaging and a nearly 60%
increase in depth of field, this state-of-the-art microscope will enhance the
surgical workflow, offering greater precision and comfort for ophthalmic
surgeons.
Building on this legacy, the newly introduced ZEISS
ARTEVO 750 will elevate surgical visualization with advanced optical
technology. Featuring new RGB LED illumination with adjustable light color
temperature and a 40% increase in resolution of data overlays within the
eyepiece, this microscope enhances clarity and precision, supporting better
intraoperative decision-making.
Introducing the AT ELANA 841P – The Next Generation
of Trifocal IOLs
As part of the ZEISS Premium Cataract Workflow, the
new AT ELANA 841P trifocal Intraocular Lens (IOL) showcases ZEISS’s expertise
in premium lens technology. Designed on a glistening-free hydrophobic c-loop
platform, the AT ELANA 841P will deliver superior visual outcomes by optimizing
intermediate and near vision, providing cataract patients with a high level of
spectacle independence and long-term performance.
AI-Driven Decision Support with ZEISS CIRRUS
PathFinder
ZEISS is also set to showcase its latest
advancement in AI-powered ophthalmic decision support – the ZEISS CIRRUS
PathFinder. This fully integrated tool harnesses proprietary deep learning
algorithms, trained by leading retina specialists, to automatically identify
abnormal macular OCT B-scans. By streamlining the pre-surgical assessment of
the retina, ZEISS CIRRUS PathFinder will optimize surgical planning and enhance
patient outcomes.
Innovation remains at the core of ZEISS. The year
2025 marks a significant step in the company’s commitment to pioneering
eye-care solutions. ZEISS India’s Medical Technology team remains confident
that the entire ecosystem will deliver exceptional value, empowering the
medical practitioner with high-end precision and data-driven solutions to
ensure better clinical outcomes.
To know more, please
visit: https://www.zeiss.com/meditec/en/home.html
For further media queries,
please contact:
Kajal Kamal | +91 9582870715 |
kajal.kamal@zeiss.com